The article provides an investment overview of Arcutus, offering insights and analysis, and ways of thinking about the investment opportunity. Arcutus is an mRNA specialist developer with no approved ...

Stocks trading under $10 rarely come with the potential for life-changing gains, especially in today’s cautious market. In ...

Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to forthcoming clinical data for both the ARCT-032 cystic fibrosis program and the ...

New Covid strain XBB.1.18, nicknamed arcturus, is quickly spreading across the U.S., but experts are warning that pink eye and high fever, two symptoms of the new variant, are particularly present ...

A new strain of coronavirus has come to town, and it’s one that behaves a little differently than its preceding variants thanks to its tendency to give people pink eye. We’re here to tell you all ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of ...

Arcturus, or XBB.1.16, is a new Omicron subvariant that is being monitored by the World Health Organization. The new subvariant is behind a recent COVID-19 surge in India and has been found in the U.S ...

Preliminary data from ongoing clinical booster study of ARCT-154 (5 mcg) shows a 50-fold increase in neutralizing antibody geometric mean concentration against SARS-CoV-2 using a validated pseudovirus ...

“Moderna lost its IPR against the ‘069 patent directed to Arbutus’s LNP delivery technology. That ruling is currently on appeal before the Federal Circuit and Moderna has nonetheless indicated that it ...

University of Westminster provides funding as a member of The Conversation UK. It’s important to note that only a small portion of COVID infections undergo genetic sequencing, so it’s likely there are ...